1398 results about "Coronary artery disease" patented technology

A method and system for non-invasive patient-specific assessment of coronary artery disease is disclosed. An anatomical model of a coronary artery is generated from medical image data. A velocity of blood in the coronary artery is estimated based on a spatio-temporal representation of contrast agent propagation in the medical image data. Blood flow is simulated in the anatomical model of the coronary artery using a computational fluid dynamics (CFD) simulation using the estimated velocity of the blood in the coronary artery as a boundary condition.

A method and composition for blood lipid therapy by administering to the subject an effective amount of a dyslipidemic agent and omega-3 fatty acids. The method utilizes a single administration or a unit dosage of a combination of dyslipidemic agent and omega-3 fatty acids for the treatment of patients with hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, coronary heart disease (CHD), vascular disease, artherosclerotic disease and related conditions, and the prevention or reduction of cardiovascular and vascular events.

Compositions that promote and / or maintain cardiovascular health through the treatment of one or more cardiovascular diseases are provided. Also provided are methods for using compositions that promote and / or maintain cardiovascular health through the prevention, stabilization, reversal and / or treatment of coronary artery disease and / or cerebrovascular disease. Such compositions may be used independently to promote and / or maintain cardiovascular health or used in combination with one or more other compositions used in the treatment of various other disease states common to aging and / or a health deteriorating condition.

CAD (computer-aided diagnosis) systems and applications for cardiac imaging are provided, which implement methods to automatically extract and analyze features from a collection of patient information (including image data and / or non-image data) of a subject patient, to provide decision support for various aspects of physician workflow including, for example, automated assessment of regional myocardial function through wall motion analysis, automated diagnosis of heart diseases and conditions such as cardiomyopathy, coronary artery disease and other heart-related medical conditions, and other automated decision support functions. The CAD systems implement machine-learning techniques that use a set of training data obtained (learned) from a database of labeled patient cases in one or more relevant clinical domains and / or expert interpretations of such data to enable the CAD systems to “learn” to analyze patient data and make proper diagnostic assessments and decisions for assisting physician workflow.

This invention relates to a method for prevention and treatment of aging, age-related disorders and / or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, type 2 diabetes, dementia and some forms of arthritis and cancer in a subject comprising administering to said subject, separately, sequentially or simultaneously a therapeutically effective dosage of each component or combination of statins, bisphosphonates, cholesterol lowering agents or techniques, interleukin-6 inhibitor / antibody, interleukin-6 receptor inhibitor / antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor / antibody, tyrosine kinases inhibitors / antibodies, serine / threonine kinases inhibitors / antibodies, mitogen-activated protein (MAP) kinase inhibitors / antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors / antibodies, Nuclear factor κB (NF-κB) inhibitors / antibodies, IκB kinase (IKK) inhibitors / antibodies, activator protein-1 (AP-1) inhibitors / antibodies, STAT transcription factors inhibitors / antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof, administered separately, in sequence or simultaneously. Inhibition of the signal transduction pathway for Interleukin 6 mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging, age-related disorders and / or age-related manifestations including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor / antibody, interleukin-6 receptor inhibitor / antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor / antibody, tyrosine kinases inhibitors / antibodies, serine / threonine kinases inhibitors / antibodies, mitogen-activated protein (MAP) kinase inhibitors / antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors / antibodies, Nuclear factor κB (NF-κB) inhibitors / antibodies, IκB kinase (IKK) inhibitors / antibodies, activator protein-1 (AP-1) inhibitors / antibodies, STAT transcription factors inhibitors / antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism, isoprenoid depletion and / or inhibition of the signal transduction pathway

This invention provides methods, devices and kits for treating coronary artery disease, particularly “soft” or vulnerable plaque. The invention is based on the local delivery of crosslinking means to crosslink the collagen covering the plaque and other proteins that may be present at the site to stabilize the plaque and prevent leakage of thrombogenic material into the lumen of the coronary artery. In certain embodiments, catheters are employed to achieve local delivery of a crosslinking agent or ultraviolet light.

Surgical methods and instruments are disclosed for performing port-access or closed-chest coronary artery bypass (CABG) surgery in multivessel coronary artery disease. In contrast to standard open-chest CABG surgery, which requires a median sternotomy or other gross thoracotomy to expose the patient's heart, post-access CABG surgery is performed through small incisions or access ports made through the intercostal spaces between the patient's ribs, resulting in greatly reduced pain and morbidity to the patient. In situ arterial bypass grafts, such as the internal mammary arteries and / or the right gastroepiploic artery, are prepared for grafting by thoracoscopic or laparoscopic takedown techniques. Free grafts, such as a saphenous vein graft or a free arterial graft, can be used to augment the in situ arterial grafts. The graft vessels are anastomosed to the coronary arteries under direct visualization through a cardioscopic microscope inserted through an intercostal access port. Retraction instruments are provided to manipulate the heart within the closed chest of the patient to expose each of the coronary arteries for visualization and anastomosis. Disclosed are a tunneler and an articulated tunneling grasper for rerouting the graft vessels, and a finger-like retractor, a suction cup retractor, a snare retractor and a loop retractor for manipulating the heart. Also disclosed is a port-access topical cooling device for improving myocardial protection during the port-access CABG procedure. An alternate surgical approach using an anterior mediastinotomy is also described.

This invention relates to a method for prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, type 2 diabetes, dementia and some forms of arthritis and cancer in a subject comprising administering to said subject, separately, sequentially or simultaneously a therapeutically effective dosage of each component or combination of statins, bisphosphonates, cholesterol lowering agents or techniques, interleukin-6 inhibitor / antibody, interleukin-6 receptor inhibitor / antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor / antibody, tyrosine kinases inhibitors / antibodies, serine / threonine kinases inhibitors / antibodies, mitogen-activated protein (MAP) kinase inhibitors / antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors / antibodies, Nuclear factor κB (NF-κB) inhibitors / antibodies, IκB kinase (IKK) inhibitors / antibodies, activator protein-1 (AP-1) inhibitors / antibodies, STAT transcription factors inhibitors / antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof, administered separately, in sequence or simultaneously. Inhibition of the signal transduction pathway for Interleukin 6 mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging and age-related disorders including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor / antibody, interleukin-6 receptor inhibitor / antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor / antibody, tyrosine kinases inhibitors / antibodies, serine / threonine kinases inhibitors / antibodies, mitogen-activated protein (MAP) kinase inhibitors / antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors / antibodies, Nuclear factor κB (NF-κB) inhibitors / antibodies, IκB kinase (IKK) inhibitors / antibodies, activator protein-1 (AP-1) inhibitors / antibodies, STAT transcription factors inhibitors / antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism, isoprenoid depletion and / or inhibition of the signal transduction pathway.

An apparatus for electrocardiogram measurement including a first non-conductive pad. A first and second electrode are disposed on the first non-conductive pad. The first electrode represents any one of V4, V5, or V6 and the second electrode is either (i) positioned on the subject below the first electrode in order to represent left leg (LL) or (ii) is placed on a line on the subject defined by the V4, V5, and V6 precordial positions in order to represent any one of V4, V5, or V6 not represented by the first electrode. The apparatus includes a second non-conductive pad. A third electrode is disposed on the second non-conductive pad. The third electrode is a right arm (RA) electrode that is for positioning at a position that is on or close to the right arm of the subject. Each electrode is adapted for electrical connection with the skin in order to receive and transmit electrical impulses. The apparatus further includes an electrical connection that connects each electrode disposed on the first and second non-conductive pads to an electrocardiological measuring apparatus. The electrocardiological measuring apparatus is capable of measuring a first lead and a different second lead without user intervention.

CAD (computer-aided diagnosis) systems and applications for cardiac imaging are provided, which implement methods to automatically extract and analyze features from a collection of patient information (including image data and / or non-image data) of a subject patient, to provide decision support for various aspects of physician workflow including, for example, automated assessment of regional myocardial function through wall motion analysis, automated diagnosis of heart diseases and conditions such as cardiomyopathy, coronary artery disease and other heart-related medical conditions, and other automated decision support functions. The CAD systems implement machine-learning techniques that use a set of training data obtained (learned) from a database of labeled patient cases in one or more relevant clinical domains and / or expert interpretations of such data to enable the CAD systems to “learn” to analyze patient data and make proper diagnostic assessments and decisions for assisting physician workflow.

The present invention relates to traditional Chinese medicine for treating coronary heart disease and stenocardia is made from (by wt.%) salvia root 50-97%, notoginseng 2-48% and borneol 0.2-3%, in which the salvia root and notoginseng and hot extracted with water, then filtering, concentrating, alcohol precipitating, standing still, recovering ethyl alcohol, concentrating, into extractum, further blended with borneol and adjuvant polyglycol-6000 to form into product.

Methods and devices are provided for applying retrograde perfusion of blood at various locations within the body. In certain exemplary embodiments, the methods and devices are particularly useful during open or translumenal surgical approaches to apply long-term retrograde perfusion of the myocardium, the neurosystem, or a periphery, such as the arm or leg, thereby treating various medical conditions, such as coronary artery disease, stroke, renal failure, etc.

A URAT1 activity inhibitor containing a nitrogen-containing fused ring compound represented by the following formula [1]: wherein each symbol is as defined in the description. The present invention is useful for the prophylaxis or treatment of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like.

This invention relates to a method for prevention and treatment of Atherosclerosis, Peripheral Vascular Disease, Coronary Artery Disease, and age-related disorders including Osteoporosis, Arthritis, Type II Diabetes, Dementia and Alzheimer's disease in a subject comprising administering to said subject a therapeutically effective dosage of each component or combination of statins, bisphosphonates, cholesterol lowering agents or techniques, interleukin-6 inhibitor / antibody, interleukin-6 receptor inhibitor / antibody, gp130 protein inhibitor / antibody, tyrosine kinases inhibitors / antibodies, STAT transcription factors inhibitors / antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof, administered separately, in sequence or simultaneously. Inhibition of the signal transduction pathway for Interleukin 6 mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging and age-related disorders including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway including interleukin-6 inhibitor / antibody, interleukin-6 receptor inhibitor / antibody, gp130 protein inhibitor / antibody, tyrosine kinases inhibitors / antibodies, STAT transcription factors inhibitors / antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism, isoprenoid depletion and inhibition of the signal transduction pathway.

The system and method of the present invention relates to using spectroscopy, for example, Raman spectroscopic methods for diagnosis of tissue conditions such as vascular disease or cancer. In accordance with a preferred embodiment of the present invention, a system for measuring tissue includes a fiber optic probe having a proximal end, a distal end, and a diameter of 2 mm or less. This small diameter allows the system to be used for the diagnosis of coronary artery disease or other small lumens or soft tissue with minimal trauma. A delivery optical fiber is included in the probe coupled at the proximal end to a light source. A filter for the delivery fibers is included at the distal end. The system includes a collection optical fiber (or fibers) in the probe that collects Raman scattered radiation from tissue, the collection optical fiber is coupled at the proximal end to a detector. A second filter is disposed at the distal end of the collection fibers. An optical lens system is disposed at the distal end of the probe including a delivery waveguide coupled to the delivery fiber, a collection waveguide coupled to the collection fiber and a lens.

Among >300 miRNAs known to date, miR-1 is considered muscle-specific. Here we show that that miR-1 overexpressed in individuals with coronary artery disease, and when overexpressed, it exacerbated arrhythmogenesis in both infarcted and normal hearts of rats whereas elimination of miR-1 by its antisense inhibitor relieved it. MiR-1 rendered slowed conduction and depolarized membrane by post-transcriptionally repressing KCNJ2 and GJA1 genes, likely accounting for its arrhythmogenic potential. Thus, miR-1 may have important pathophysiological functions in heart, being a novel antiarrhythmic target useful in the treatment and prevention of various cardiac pathologies.

Disclosed are novel compounds of Formula Iuseful for treating various disease states, in particular, insulin resistance, diabetes, dyslipidemia, coronary artery disease, and inflammation. The compounds of the present invention elevate cellular expression of the ABCA-1 gene as well as increasing the level of ABCA-1 protein, which may result in an increase in HDL levels in the plasma of a mammal, in particular humans.

A method for treating a patient may include treating coronary artery disease in combination with angina pectoris and / or the control of angina pain by delivering chemical and / or electrical stimulation pulses to the cardiac and / or nervous tissue of the patient in a coordinated manner. A system for treating a patient suffering from coronary artery disease and angina may include a stimulator that generates at least one pulse in accordance with prescribed parameters, a catheter, a lead, and / or a sensor.

The object of this invention is to provide a metal stent used for insertion into a coronary artery to treat a patient suffering from angina pectoris or myocardial infarction due to a coronary artery disease. This stent consists of a plurality of primary stent units (1), each having a zigzag shape rounded at its bent portions and being expandable in a circumferential direction. The primary stent units (1) are assembled into a single cylindrical structure of the stent such that each two primary stent units (1) are integrated into one secondary stent unit by a first strut (2′) or (2″) connecting each projected bent portion of each of the two primary stent units (1) to an associated bent portion of the other. Each two secondary stent units are integrated into a desired stent by a plurality of hook-shaped second struts (3) connecting the projected bent portions of the two secondary stent units to each other.

Metallic stents which have a randomly oriented microstructure, and possess quasi-isotropic mechanical and physical properties are disclosed. The novel stents can be “tailor-made” to mimic the geometry of the blood vessel(s) at the deployment site and can be designed to treat coronary artery disease at the point where blood vessels branch. The metallic materials of choice are ductile, corrosion resistant and exhibit little crystallographic texture. The novel stents can be produced from a metallic precursor which is quasi-isotropic and exhibits little texture by processing means, such as machining, which do not reintroduce texture. Alternatively, quasi-isotropic and low texture stents are achieved by suitable post-processing of conventionally fabricated stent materials.

A system and method for acoustic detection of coronary artery disease (CAD) are provided. The system includes a transducer for acoustically detecting heart signals of a patient and a computer system which executes detection software for processing the detected heart signals to identify the presence of CAD from the heart signals. The software allows for the automatic definition of a diastolic “window” of the acoustic signal for analysis, and automatically edits the sampled acoustic signal to eliminate unwanted artifacts and / or noise in the acoustic signal. The edited signal is then processed by a plurality of signal processing algorithms, including spectral analysis algorithms, time-frequency algorithms, global feature algorithms, kurtosis algorithms, mutual information algorithms, negenthropy algorithms, and principal component analysis algorithms, to generate a disease vector. The disease vector is then classified to determine whether CAD is present in the patient. Classification can be accomplished using linear discriminant analysis or a support vector machine.

[Problems] The present invention provides a superior production method and a superior purification method of compounds effective for the treatment or prophylaxis of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like. [Means] A compound represented by the following formula [2] or a pharmaceutically acceptable salt thereof can be produced by reacting a compound represented by the following formula [3] or a salt thereof with a compound represented by the following formula [4], a salt thereof or a reactive derivative thereof. Moreover, crystallization of a compound represented by the formula [2] can be performed with industrially superior workability, and high quality crystals of a compound represented by the formula [2] can be obtained. wherein each symbol is as defined in the description.

The present invention relates to certain pharmaceutical compositions of a 5-HT2A serotonin receptor modulator and methods for preparing pharmaceutical composition related thereto. The pharmaceutical compositions are useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.

This invention provides methods, devices and kits for treating coronary artery disease, particularly “soft” or vulnerable plaque. The invention is based on the local delivery of crosslinking means to crosslink the collagen covering the plaque and other proteins that may be present at the site to stabilize the plaque and prevent leakage of thrombogenic material into the lumen of the coronary artery. In certain embodiments, catheters are employed to achieve local delivery of a crosslinking agent or ultraviolet light.

This invention also provides a method to prevent, control, and treata lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.

A method and apparatus for treating gum disease includes a light producing dental appliance that is accessible exteriorly of the body for placement within the mouth of the patient to expose the mouth to light radiation of a selected wavelength and in an amount that is effective for killing or debilitating pathogenic microorganisms and especially Porphyromona gingivalis within the mouth of the patient such that the bacterial load carried to the heart is diminished thereby reducing or eliminating the symptoms of coronary artery disease, atherosclerosis vascular inflammation and plaque formation.

Methods and devices for improved targeting to a site in an organism, particularly to a tumor target site and for extracorporeal affinity adsorption, particularly in the treatment of cancer, atherosclerosis, including coronary artery disease, unstable angina, other acute ischemic syndromes and idiopathic dilated cardiac myopathy. In one aspect of the invention, a combination is provided comprising an extracorporeal device (1) having contained therein a binding compound (11) bound to a carrier (9), the binding compound having affinity for a binding partner, and a plurality of affinity binders (15), each of said affinity binders comprising a first portion (19) comprising the binding partner and a second portion (17) adapted to bind selectively with a species, the second portions of each of said affinity binders differing from each other.

A system (AtheroEdgeLink™) that links and predicts the Syntax Score for Coronary Artery Disease Patients using carotid IMT in Ultrasound. Ultrasound is acquired for the carotids and CIMT is estimated using AtheroEdge™. For the same images, plaque burden or plaque score is estimated. Syntax score is estimated from cardiac X-ray angiograms. The AtheroEdgeLink™ technique correlates between CIMT computed using AtheroEdge™ and Syntax Score. The system AtheroEdgeLink™ can help compute the ROC area under the curve (Az) between CIMT and Syntax Score for Coronary Artery Disease patients. Such a system can also help to find the specificity of finding the threshold on CIMT for associating the presence of Coronary Artery Disease.

Compositions for the prevention and treatment of obesity, cardiovascular and coronary artery diseases are provided. The present invention provides compositions comprising at least one dibenzo-p-dioxine derivatives having inhibition ability against diacylglycerol acyltransferase (DGAT), and also provides the use of the compositions as a component of drugs or dietary supplements intended for the prevention and treatment of obesity, cardiovascular and coronary artery diseases. Since the compositions of the invention are nontoxic, allowing their chronic ingestion, easier and natural control of obesity and related diseases frequently found in obese people can be realized.